POSTER PRESENTATION



Open Access

Quantification of cAMP and cGMP analogs in intact cells: pitfals in enzyme immunoassays for cyclic nucleotides

Katharina Werner^{1*}, Frank Schwede², Hans-Gottfried Genieser², Jörg Geiger¹, Elke Butt^{1*}

From 5th International Conference on cGMP: Generators, Effectors and Therapeutic Implications Halle, Germany. 24-26 June 2011

Background

The present work evaluates the cross-reactivity of commercially available cyclic nucleotide analogs with cAMPand cGMP-immunoassays from Cayman, IBL (both IBL International, Hamburg, Germany) and ENZO Life Sciences (Loerrach, Germany).

Results and conclusion

Most of the tested cyclic nucleotide analogs showed low degree competition with the antibodies; however, with Rp-cAMPS, 8-Br-cGMP and 8-pCPT-cGMP a strong cross-reactivity with the ENZO cAMP- respectively cGMP-EIA and the IBL cGMP-RIA was observed (Table

Analog	Log K _w	Permeability	Specificity ENZO cAMP-EIA	Specificity ENZO cAMP-EIA	Specificity IBL cGMP-RIA	Specificity Cayman cGMP-EIA
2'-dcGMP	0.65	0%		5.21%		
cGMP	0.77			100%	100%	100%
Rp-cGMPS	0.89			0.27%	10.6%	
2'-dcAMP		0%	2.4%			
cAMP	1.09		100%			
8-Br-cGMP	1.17	12.1%		490%	20%	0.5%
Rp-cAMPS	1.21	12.2%	68%			
8-Br-cAMP	1.35	8.0%	0.4%			
Rp-8-Br-cAMPS	1.47		0.3%			
6-MB-cAMP	1.64		0.4%			
6-Bnz-cAMP	1.9		0.6%			
8-pCPT-cGMP	2.52	19.6%		240%	30%	0.008%
8-pCPT-cAMP	2.65	22.0%	0.05%			
8-Br-PET-cGMP	2.83	30.9%		10%	0.15%	1.6%
Rp-8-Br-PET-cGMPS	2.83			0.2%		
8-pCPT-2'-OMe-cAMP (Epac Activator)	2.94		0.03%	0.02%		
Sp-5,6-DCI-cBIMPS	2.99		<0.001%			

Table 1 Lipophilicity (log K_w), cell permeability and EIA/RIA specificity of selected cyclic Nucleotide analogs.

* Correspondence: butt@klin-biochem.uni-wuerzburg.de

¹Institute for Clinical Biochemistry and Pathobiochemistry, University of Wuerzburg, Germany

Full list of author information is available at the end of the article



© 2011 Werner et al; licensee BioMed Central Ltd. This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

1). As a consequence we tested these derivatives with the Cayman cGMP-EIA. This assay is less sensitive to cGMP (1.0 pmol/ml) than the ENZO cGMP-EIA (0.01 pmol/ml), however the specificity concerning cGMP-analogs is superior and therefore advantageous when measuring cGMP in the presence of 8-Br-cGMP or 8-pCPT-cGMP.

The determined EIA binding constants enabled the measurement of the intracellular cyclic nucleotide concentrations and revealed a time- and lipophilicity-dependent cell membrane permeability of the compounds in the range of 10-30 % of the extracellular applied concentration after 20 min (Table 1).

Author details

¹Institute for Clinical Biochemistry and Pathobiochemistry, University of Wuerzburg, Germany. ²Biolog Life Science Institute, Flughafendamm 9a, D-28199 Bremen, Germany.

Published: 1 August 2011

doi:10.1186/1471-2210-11-S1-P75

Cite this article as: Werner *et al.*: **Quantification of cAMP and cGMP analogs in intact cells: pitfals in enzyme immunoassays for cyclic nucleotides.** *BMC Pharmacology* 2011 **11**(Suppl 1):P75.

Submit your next manuscript to BioMed Central and take full advantage of:

- Convenient online submission
- Thorough peer review
- No space constraints or color figure charges
- Immediate publication on acceptance
- Inclusion in PubMed, CAS, Scopus and Google Scholar
- Research which is freely available for redistribution

BioMed Central

Submit your manuscript at www.biomedcentral.com/submit